We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

Expanded access is no longer available for this treatment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00801515
First Posted: December 3, 2008
Last Update Posted: July 25, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Pfizer
Information provided by:
ViiV Healthcare
December 2, 2008
December 3, 2008
July 25, 2011
 
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.
Not Provided
Expanded Access
Drug: Maraviroc
150 mg twice per day
Other Name: Celsentri
Not Provided
 
No longer available
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00801515
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ViiV Healthcare
Pfizer
Study Director: Pfizer CT.gov Call Center Pfizer
ViiV Healthcare
July 2011